Julie White was educated in the UK and has a Masters Degree in Social Policy from the London School of Economics. She spent many years as an independent researcher, writing articles and reports and four books, including “Sisters and Solidarity: Women and Unions in Canada” (Thompson Educational Publishing, 1993). She also worked in the Research Department of the Communications, Energy and Paperworkers Union of Canada (now part of Unifor).
She has sat on the Board of the Canadian Health Coalition for 15 years, currently representing the Congress of Union Retirees of Canada. She is also the author of the Coalition’s policy document called “A National Public Drug Plan for All”.
Day 1: Oct 6, 2020
Day 2: Oct 7, 2020
Day 3: Oct 8, 2020
Keynote Address: Where is Pharmacare?
Gain Insight into the Impact of Covid-19 on Access to Prescription Medication
The economic impact of the pandemic has been significant for many Canadians, but devastating to those who have lost their jobs and the drug benefit plans they relied on for treatment for their own medical conditions or those of their families. More than a year has elapsed since the report “A Prescription for Canada: Achieve Pharmacare for All” was issued, and lately it has disappeared from the Federal agenda. Hear why, as the post-pandemic future emerges, Canadians need it now more than ever. Shape your market access strategy by:
- Understanding the impact of Covid-19 on Canadians’ access to prescription medications
- What steps are currently being taken to encourage the federal government to implement the recommendations in their report
- What impact implementation may have on Canada’s pharma industry and whether it may need to be coordinated with the launch of the new PMPRB pricing regulations
Get valuable insights on the impact of Covid-19 on how, or whether Canadians can access prescription medication